液体甲状腺素改善了小肠细菌过度生长和刺激性肠综合征的甲状腺下降患者的结果
Brittany Bohinc Henderson1, Shelby P Smith1, Marlena E Mengelkamp1
1Charleston Thyroid Center, Mount Pleasant, South Carolina.
概括
液体勒沃甲状腺素 (LT4) 改善甲状腺控制和胃肠道 (GI) 症状在患有甲状腺功能低下症和刺激性肠综合征 (IBS) 的患者,特别是那些小肠细菌过度生长 (SIBO). 切换到液体LT4使甲状腺水平正常化,并缓解了许多患者的IBS症状.
科学领域:
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 利沃甲状腺素 (LT4) 吸收不良常见于患有肠道疾病的甲状腺功能低下症.
- 刺激性肠综合征 (IBS) 经常与甲状腺功能低下症同时发生.
- 小肠细菌过度生长 (SIBO) 可能导致LT4吸收不良.
研究的目的:
- 为了确定患有甲状腺功能低下症和IBS的患者中SIBO的患病率.
- 为了比较液体LT4与片剂配方的吸收一致性.
- 评估液体LT4对甲状腺和胃肠道症状控制的影响.
主要方法:
- 75名患有甲状腺功能低下症和IBS的成年患者的前性,开放式,单中心研究.
- 患者从LT4片剂转换为相当的液体LT4剂量.
- 在12周内监测甲状腺水平,IBS症状和便特征;在6周后进行SIBO呼吸测试.
主要成果:
- 在研究人群中,SIBO患病率为65.3%.
- 液体LT4在77.55%的患者中使TSH正常化,而在片剂中为57.14%.
- 液体LT4改善了甲状腺功能低下和IBS症状,便的外观和肠道频率,特别是在SIBO患者中.
结论:
- 在患有甲状腺功能低下和IBS的患者中,SIBO的流行率很高.
- 液体LT4在这个人群中提供了比平板电脑更稳定的吸收和更好的甲状腺控制.
- 液体LT4显著改善胃肠道症状,并可以导致一些患者的IBS症状完全消失.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Irritable Bowel Syndrome I: Introduction
273
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
273
Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Irritable Bowel Syndrome III: Medical and Nursing Management
202
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
202
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
160
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
160


